Alliancebernstein L.P. increased its stake in shares of Catalent Inc (NYSE:CTLT) by 64.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 245,219 shares of the company’s stock after buying an additional 96,400 shares during the quarter. Alliancebernstein L.P. owned about 0.17% of Catalent worth $11,170,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Massachusetts Financial Services Co. MA grew its position in shares of Catalent by 15.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 15,152 shares of the company’s stock worth $635,000 after buying an additional 2,075 shares during the period. TD Asset Management Inc. grew its position in shares of Catalent by 5.1% during the 2nd quarter. TD Asset Management Inc. now owns 319,380 shares of the company’s stock worth $13,379,000 after buying an additional 15,607 shares during the period. Public Employees Retirement Association of Colorado grew its position in shares of Catalent by 30.6% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 21,048 shares of the company’s stock worth $882,000 after buying an additional 4,929 shares during the period. Virginia Retirement Systems ET AL grew its position in shares of Catalent by 83.1% during the 2nd quarter. Virginia Retirement Systems ET AL now owns 39,000 shares of the company’s stock worth $1,634,000 after buying an additional 17,700 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Catalent during the 2nd quarter worth about $1,508,000. 96.77% of the stock is currently owned by hedge funds and other institutional investors.
In other Catalent news, insider Barry Littlejohns sold 47,265 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $41.64, for a total transaction of $1,968,114.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Donald E. Morel, Jr. purchased 10,000 shares of Catalent stock in a transaction on Thursday, September 13th. The shares were purchased at an average cost of $43.00 per share, with a total value of $430,000.00. The disclosure for this purchase can be found here. Insiders sold a total of 184,335 shares of company stock valued at $8,161,727 over the last quarter. 1.40% of the stock is owned by insiders.
Shares of CTLT opened at $36.32 on Friday. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.05 and a quick ratio of 1.61. Catalent Inc has a 52-week low of $34.24 and a 52-week high of $47.87. The company has a market capitalization of $5.53 billion, a P/E ratio of 22.84, a price-to-earnings-growth ratio of 2.38 and a beta of 1.44.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 6th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.04. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The business had revenue of $551.80 million during the quarter, compared to analyst estimates of $582.44 million. During the same period in the previous year, the firm earned $0.21 EPS. Catalent’s quarterly revenue was up 1.5% compared to the same quarter last year. Equities analysts forecast that Catalent Inc will post 1.63 EPS for the current year.
Several equities analysts have recently issued reports on CTLT shares. JPMorgan Chase & Co. boosted their target price on Catalent from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 29th. Zacks Investment Research lowered Catalent from a “hold” rating to a “sell” rating in a research report on Monday, September 3rd. UBS Group began coverage on Catalent in a research report on Tuesday, October 9th. They issued a “neutral” rating and a $48.00 price objective for the company. ValuEngine lowered Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, November 6th. Finally, First Analysis upgraded Catalent from a “neutral” rating to an “outperform” rating and decreased their price objective for the company from $47.00 to $43.00 in a research report on Wednesday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $48.00.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Recommended Story: Preferred Stock
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.